306 related articles for article (PubMed ID: 28858075)
1. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.
Aboudaram A; Modesto A; Chaltiel L; Gomez-Roca C; Boulinguez S; Sibaud V; Delord JP; Chira C; Delannes M; Moyal E; Meyer N
Melanoma Res; 2017 Oct; 27(5):485-491. PubMed ID: 28858075
[TBL] [Abstract][Full Text] [Related]
2. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
[TBL] [Abstract][Full Text] [Related]
5. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial.
Levy A; Massard C; Soria JC; Deutsch E
Eur J Cancer; 2016 Nov; 68():156-162. PubMed ID: 27764686
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
Kropp LM; De Los Santos JF; McKee SB; Conry RM
J Immunother; 2016; 39(9):373-378. PubMed ID: 27662339
[TBL] [Abstract][Full Text] [Related]
7. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
Funck-Brentano E; Baghad B; Fort M; Aouidad I; Roger A; Beauchet A; Otmezguine Y; Blom A; Longvert C; Boru B; Saiag P
Int J Cancer; 2020 Sep; 147(6):1707-1714. PubMed ID: 32083739
[TBL] [Abstract][Full Text] [Related]
10. Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.
Heidelberger V; Goldwasser F; Kramkimel N; Jouinot A; Franck N; Arrondeau J; Guégan S; Mansuet-Lupo A; Alexandre J; Damotte D; Avril MF; Dupin N; Aractingi S
Invest New Drugs; 2017 Dec; 35(6):842-847. PubMed ID: 28569347
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study.
Mowery YM; Patel K; Chowdhary M; Rushing CN; Roy Choudhury K; Lowe JR; Olson AC; Wisdom AJ; Salama JK; Hanks BA; Khan MK; Salama AKS
Radiother Oncol; 2019 Sep; 138():114-120. PubMed ID: 31252292
[TBL] [Abstract][Full Text] [Related]
12. Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition.
Trommer M; Yeo SY; Persigehl T; Bunck A; Grüll H; Schlaak M; Theurich S; von Bergwelt-Baildon M; Morgenthaler J; Herter JM; Celik E; Marnitz S; Baues C
Front Pharmacol; 2019; 10():511. PubMed ID: 31156434
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
14. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.
Sibaud V; David I; Lamant L; Resseguier S; Radut R; Attal J; Meyer N; Delord JP
Melanoma Res; 2015 Dec; 25(6):555-8. PubMed ID: 26312439
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibition for advanced mucosal melanoma.
Thierauf J; Veit JA; Hess J; Treiber N; Lisson C; Weissinger SE; Bommer M; Hoffmann TK
Eur J Dermatol; 2017 Apr; 27(2):160-165. PubMed ID: 28174141
[TBL] [Abstract][Full Text] [Related]
17. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer.
Britschgi C; Riesterer O; Burger IA; Guckenberger M; Curioni-Fontecedro A
Radiat Oncol; 2018 May; 13(1):102. PubMed ID: 29855323
[TBL] [Abstract][Full Text] [Related]
18. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
[TBL] [Abstract][Full Text] [Related]
20. Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy.
Gabani P; Robinson CG; Ansstas G; Johanns TM; Huang J
Radiother Oncol; 2018 May; 127(2):310-317. PubMed ID: 29534829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
